These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34117084)

  • 1. Vaccines and Disease Relapses in Children with Nephrotic Syndrome.
    Angeletti A; Bruschi M; Bianchin S; Bonato I; Montobbio C; Verrina E; Lugani F; Cravedi P; Ghiggeri GM
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):937-938. PubMed ID: 34117084
    [No Abstract]   [Full Text] [Related]  

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P; Colucci M; Bruschi M; Vivarelli M; Cioni M; DiDonato A; Cravedi P; Lugani F; Antonini F; Prunotto M; Emma F; Angeletti A; Ghiggeri GM
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of patients with early relapse during B-cell depletion after rituximab treatment for complicated steroid-dependent nephrotic syndrome.
    Fujinaga S; Endo S; Onuki Y
    Clin Exp Nephrol; 2021 Apr; 25(4):441-442. PubMed ID: 33409760
    [No Abstract]   [Full Text] [Related]  

  • 4. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
    Sato M; Kamei K; Ogura M; Ishikura K; Ito S
    Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Cascioli S; Casiraghi F; Perna A; Ravà L; Ruggiero B; Emma F; Vivarelli M
    J Am Soc Nephrol; 2016 Jun; 27(6):1811-22. PubMed ID: 26567244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A; Calatroni M; D'Alessandro M; Signa S; Bertelli E; Cioni M; Di Marco E; Biassoni R; Caridi G; Ingrasciotta G; Bertelli R; Di Donato A; Bruschi M; Canepa A; Piaggio G; Ravani P; Ghiggeri GM
    Br J Clin Pharmacol; 2018 Jun; 84(6):1238-1249. PubMed ID: 29436729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
    Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
    Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
    BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in steroid-dependent nephrotic syndrome.
    El Koumi M
    Iran J Kidney Dis; 2013 Nov; 7(6):502-6. PubMed ID: 24241100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
    Greenberg DP; Doemland M; Bettinger JA; Scheifele DW; Halperin SA; ; Waters V; Kandola K
    Pediatr Infect Dis J; 2009 Jun; 28(6):521-8. PubMed ID: 19436236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?
    Delbet JD; Leclerc G; Ulinski T
    Pediatr Nephrol; 2019 Mar; 34(3):529-532. PubMed ID: 30542932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
    Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
    [No Abstract]   [Full Text] [Related]  

  • 19. Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.
    Lemley KV; Mak RH
    Nat Rev Nephrol; 2015 May; 11(5):257-8. PubMed ID: 25752834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
    Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.